Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia

Table 2

Clinical characteristics of pediatric patients with ALL (BM samples).

Sex	Male	64.0% (n = 55)
	Female	36.0% (n = 31)
Age (at ND)		5.00 ± 2.89
WBC number (at ND)		12.41 (1.74–316)
Blast cells in CSF	Negative	94.2% (n = 81)
(at ND)	CNS2	2.4% (n = 2)
	CNS3	3.5% (n = 3)
Percentage of blast cells in BM puncture (at ND)		91.46 ± 6.72%
Immunophenotyping	Common B cell	86.0% (n = 74)
	Pre B cell	7.0% (n = 6)
	Pre B cell	5.8% (n = 6)
Fusion gene	BCR-ABL	2.3% (n = 2)
	E2A-PBX1	14.0% (n = 12)
	TEL-AML1	20.3% (n = 23)
Risk stratification	Standard-risk	33.7% (n = 29)
	Intermediate-risk	55.8% (n = 48)
	High-risk	10.5% (n = 9)
CNS involvement	Yes	8.1% (n = 7)
	No	91.9% (n = 79)
Prednisone response on Day 8	Favorable	97.7% (n = 84)
	Poor^1	2.0% (n = 2)
BM response on day 15 by morphology	Non-remission	7.0% (n = 6)
	PR	11.6% (n = 10)
	CR	81.4% (n = 70)
BM response on day 33 by morphology	Non-remission	1.2% (n=1)
	PR^2	1.2% (n=1)
	CR	97.7% (n=84)

ALL: acute lymphoblastic leukemia; BM: bone marrow; CR: complete remission; CNS: central nervous system; CSF: cerebrospinal fluid; WBC: white blood cell; ND: new diagnosis; PR: partial remission.
The patients were classified as standard-risk, intermediate-risk, and high-risk groups according to age, WBC count, immunophenotype, cytogenetic and molecular aberrations, prednisone response, morphological remission at the end of induction therapy (based on BFM risk criteria), and minimal residual disease (MRD) at the end of induction therapy and the beginning of consolidation therapy [24–27].
¹When blasts are <1000/µl.
²The patient with PR on day 33 finally achieved CR 6 months after admission to the hospital.